FDA Will Cease Plasma-Derived Product Quarantine For CJD Investigations
Executive Summary
FDA will immediately release blood products quarantined for Creutzfeldt-Jakob Disease investigation, Office of Blood Research and Review Director Jay Epstein, MD, told the HHS Advisory Committee on Blood Safety and Availability Aug. 27. FDA had required manufacturers to quarantine blood and plasma-derived products while the agency investi- gated whether a donor to the blood pool from which the product was made was at increased risk of CJD.